echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zejing Pharmaceutical: Disclosure of research and development progress of Donafinil tosylate tablets

    Zejing Pharmaceutical: Disclosure of research and development progress of Donafinil tosylate tablets

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the 16th, Zejing Pharmaceutical issued an announcement stating that Donafinil Tosylate Tablets is a multi-center, randomized, double-blind, placebo-controlled treatment of locally advanced/metastatic radioiodine refractory differentiated thyroid cancer (RAIR-DTC) The Phase III clinical trial (code name: ZGDD3) carried out a preset interim analysis, and the Independent Data Monitoring Committee (IDMC) reviewed the results and determined that the effectiveness and safety results were in line with expectations


    After communicating with the Drug Evaluation Center of the National Medical Products Administration, the company has obtained CDE's approval to terminate the ZGDD3 trial ahead of schedule.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.